Archive
All News
Every briefing, headline, and filing we've published, newest first.
Negotiations
The 2026 FTC settlement compels Express Scripts to base patient costs on net, not list, prices—ending the reba…
Negotiations
AssistRx says half of its 2025 patient support programs came via hub transitions, underscoring deep vendor con…
NegotiationsBriefing
The 2026 exclusion lists from Caremark, Express Scripts, and Optum Rx favor private-label biosimilars and lowe…
PolicyFiercePharma ↗
The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing …
MoneyFierceBiotech ↗
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pan…
PeopleBriefing
Matthew Lang, who steered Metsera’s $10B sale to Pfizer, joins Structure Therapeutics as COO and GC, as Vir an…
PeopleBriefing
Astellas trims stem cell research, GSK accelerates its ADC program, Daiichi exits OTC, Takeda ends mRNA pact, …
DataBriefing
New KFF data show 165.6M Americans under 65 had employer coverage in March 2025, yet only 22.5% of those below…
PeopleFiercePharma ↗
AI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link betwe…
PolicyFiercePharma ↗
The FDA should strengthen the evidence required for drug approvals under its accelerated pathway, and increase…
DealsFiercePharma ↗
With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in p…
NegotiationsFiercePharma ↗
A prominent physician voice in the House of Representatives has introduced a new bill that would compel insure…
PipelineFierceBiotech ↗
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clin…
MoneyFierceBiotech ↗
Abbott's first-quarter numbers reflect is operational complexity.…
MoneyFierceBiotech ↗
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to conti…
MoneyFierceBiotech ↗
The Spanish government has announced a goal to raise a $200 million venture capital fund to launch the Spain-B…
MoneyFierceBiotech ↗
The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing fro…
PolicyFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
PipelineFierceBiotech ↗
Many gene therapy outfits focus on technical advances, Ocugen CEO Shankar Musunuri, Ph.D., said, meaning they …
PipelineFiercePharma ↗
Rather than relying on patient groups to make an impassioned plea, Roche aims to put doubts to rest around the…
PipelineFiercePharma ↗
Travere is eyeing a collective $3 billion U.S. opportunity for Filspari thanks to a new rare kidney disease no…
MoneyFiercePharma ↗
Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest…
PipelineFierceBiotech ↗
After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning t…
PolicyFiercePharma ↗
The legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.